TEST BANK
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A researcher observes that an extract from a medicinal plant
consistently reduces fever in laboratory models. What is the most
appropriate next step in a drug-discovery program?
A. Immediately market the plant extract as a therapeutic product
B. Identify and characterize the active chemical constituents responsible
for the effect
,C. Replace the extract with a structurally unrelated synthetic compound
D. Begin human trials before determining which constituents are
pharmacologically active
Correct Answer: B
Rationale:
B is correct because identifying the active constituent(s) transforms an
empirically observed biological effect into a defined chemical starting
point for drug discovery. This enables characterization of the
compound's mechanism, potency, selectivity, pharmacokinetics, and
safety. A is inappropriate because crude extracts may contain multiple
active or toxic substances and require rigorous characterization before
clinical use. C discards potentially useful structural information rather
than exploiting the observed activity. D is premature because a defined
active agent and adequate preclinical evidence are generally needed
before clinical development.
Question 2
Which characteristic most directly distinguishes a lead compound from
a drug that is ready for routine clinical use?
A. The lead compound has demonstrated some useful biological activity
but may still require optimization
B. The lead compound must already have maximal potency and
selectivity
C. The lead compound has completed all required clinical trials
D. The lead compound is necessarily derived from a medicinal plant
Correct Answer: A
, Rationale:
A is correct because a lead compound is a promising chemical entity
that provides a starting point for optimization of potency, selectivity,
pharmacokinetics, and safety. B is incorrect because lead compounds
frequently have liabilities that must be improved. C describes an
approved or late-stage therapeutic rather than a lead. D is incorrect
because leads may arise from natural products, synthetic libraries,
biological screening, or computer-aided approaches.
Question 3
A natural product demonstrates strong activity against a molecular
target. Chemists then produce several structurally related analogs and
compare their biological activity. What major drug-discovery concept is
being applied?
A. Structure-activity relationship analysis
B. Therapeutic drug monitoring
C. Receptor downregulation
D. Drug elimination
Correct Answer: A
Rationale:
A is correct because structure-activity relationship (SAR) studies
examine how chemical modifications influence biological activity. This
helps investigators identify structural features required for potency or
selectivity and guides rational optimization. B concerns monitoring drug
concentrations in patients. C describes a biological adaptation to
sustained receptor stimulation or related influences. D is a
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A researcher observes that an extract from a medicinal plant
consistently reduces fever in laboratory models. What is the most
appropriate next step in a drug-discovery program?
A. Immediately market the plant extract as a therapeutic product
B. Identify and characterize the active chemical constituents responsible
for the effect
,C. Replace the extract with a structurally unrelated synthetic compound
D. Begin human trials before determining which constituents are
pharmacologically active
Correct Answer: B
Rationale:
B is correct because identifying the active constituent(s) transforms an
empirically observed biological effect into a defined chemical starting
point for drug discovery. This enables characterization of the
compound's mechanism, potency, selectivity, pharmacokinetics, and
safety. A is inappropriate because crude extracts may contain multiple
active or toxic substances and require rigorous characterization before
clinical use. C discards potentially useful structural information rather
than exploiting the observed activity. D is premature because a defined
active agent and adequate preclinical evidence are generally needed
before clinical development.
Question 2
Which characteristic most directly distinguishes a lead compound from
a drug that is ready for routine clinical use?
A. The lead compound has demonstrated some useful biological activity
but may still require optimization
B. The lead compound must already have maximal potency and
selectivity
C. The lead compound has completed all required clinical trials
D. The lead compound is necessarily derived from a medicinal plant
Correct Answer: A
, Rationale:
A is correct because a lead compound is a promising chemical entity
that provides a starting point for optimization of potency, selectivity,
pharmacokinetics, and safety. B is incorrect because lead compounds
frequently have liabilities that must be improved. C describes an
approved or late-stage therapeutic rather than a lead. D is incorrect
because leads may arise from natural products, synthetic libraries,
biological screening, or computer-aided approaches.
Question 3
A natural product demonstrates strong activity against a molecular
target. Chemists then produce several structurally related analogs and
compare their biological activity. What major drug-discovery concept is
being applied?
A. Structure-activity relationship analysis
B. Therapeutic drug monitoring
C. Receptor downregulation
D. Drug elimination
Correct Answer: A
Rationale:
A is correct because structure-activity relationship (SAR) studies
examine how chemical modifications influence biological activity. This
helps investigators identify structural features required for potency or
selectivity and guides rational optimization. B concerns monitoring drug
concentrations in patients. C describes a biological adaptation to
sustained receptor stimulation or related influences. D is a
